OCT 30, 2014 1:30 PM PDT

Dissecting cancer signaling pathways with chemical scalpels

Speaker
  • Head, Synthetic Biologics Core, Cancer and Inflammation Program, Center for Cancer Research National Cancer Institute
    Biography
      Dr. Tarasova was trained as a bioorganic chemist. She obtained her Ph.D. in chemistry at Lomonosov University, Moscow, Russia in 1981. After post-doctoral training in the lab of Prof. Bent Foltmann at Copenhagen University, Denmark, she established a group working on the chemistry of proteolytic enzymes in the Chemistry Department of Lomonosov University. Dr. Tarasova joined the ABL-Basic Research Program of NCI as Visiting Scientist in 1991 and became a Staff Scientist in NCI Center for Cancer Research in 1999. She was appointed a Head of Synthetic Biologics and Drug Discovery Facility in 2008.

    Abstract

    Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is progressing much slower. Incomplete knowledge of oncoproteins regulatory mechanisms results in unexpected detrimental effects of targeted therapy. Obliteration of the protein expression is the most commonly used approach in characterization of protein function. However, the majority of proteins have multiple functions and many interacting partners. Genetic eradication of proteins does not inform on the function of particular protein-protein interactions and cannot detect essential self-inhibitory mechanisms. Chemical biology tools are much more informative in that sense. However, generation of selective chemical probes is a labor-intense process. In addition, the majority of protein-protein interactions cannot be inhibited by small molecules and thus are considered undruggable. Peptides are well suited for targeting protein-protein interactions, but their use is hampered by conformational flexibility, poor membrane penetration, low stability in circulation and rapid clearance from the body. We and others we have succeeded recently in developing metabolically stable cell permeable peptide analogs with rigid and predictable structures amenable to rational design. The approach developed in our group is based on structural stabilization of protein fragments by membrane anchoring. General applicability of this straightforward method was confirmed by generation of selective and highly potent dominant negative inhibitors of RAS oncogenes, ?-catenin, STAT1, STAT3 and STAT5 N-domains, and other non-druggable targets. Much simplified generation of selective chemical biology tools allows for effective interrogation of protein-protein interactions leading to uncovering of mechanistic details of molecular signaling that could not be obtained with the help of genetic approaches.

    Learning objectives:

    • Learn simple ways of developing chemical biology tools (no sophisticated chemistry is required)
    • Learn how to uncover the roles of a certain protein-protein interaction.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources